In this interview, Richard J. Nowak, MD, MS, principal investigator of the MINT trial of inebilizumab for generalized myasthenia gravis (gMG), discusses the trial’s key findings, including significant ...

The forthcoming multicenter, randomized, double-blind, placebo-controlled study will enroll up to 90 patients to evaluate the effectiveness and safety of monthly IM-101 dosing in relieving ...

The National Institute for Health and Care Excellence (NICE) recommended the drug not be used by the NHS due to its ...

People have been let down by a system that continues to put up barriers to accessing treatments that could significantly ...

Myasthenia gravis (MG) should be subgrouped into early-onset, late-onset, thymoma, ocular, anti-MuSK, anti-LRP4 and antibody-negative MG. MG has a prevalence of 140 per million, and an annual ...

Town Players of Newtown continued its 2025 season with a play written and directed by Gene Golaszewski titled Double Vision that opened last weekend at The Little Theatre.. Double Vision is a farce, a ...

Background Myasthenia Gravis (MG) is an autoimmune disorder presenting with fatigable muscle weakness leading to potential respiratory distress. Clinical management aims to improve patient quality of ...

Myasthenia gravis affects both men and women and occurs across all races and ethnicities. Its incidence and prevalence are higher in women under age 50 and in men ages 65 and older.

People with generalized myasthenia gravis (MG) experience psychiatric symptoms including anxiety, depression, and post-traumatic stress disorder (PTSD) at rates higher than that of the general ...

Concluding a recent interview with Jonathan Strober, MD, an investigator on the phase 2/3 Vibrance-MG study (NCT05265273) exploring pediatric use of nipocalimab for generalized myasthenia gravis ...

The NHS webpage on myasthenia gravis may be a good place to find out more. These organisations can give you advice and support: Myaware, 01332 290 219; Muscular Dystrophy UK, 0800 652 6352; You can ...